Cormedix INC Schedule 13G passive stakes

Individual investor Aymen Shaibatalhamd has filed an amendment reporting a 5.9% beneficial ownership stake in CorMedix Inc.

Individual investor Aymen Shaibatalhamd has filed an amended Schedule 13G reporting a 5.9% beneficial ownership stake in CorMedix Inc.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have collectively reported beneficial ownership of 7.94% of CorMedix Inc.'s common stock as of March 31, 2026.

The Vanguard Group reports 0% beneficial ownership in CorMedix Inc. following an internal realignment that disaggregated reporting.

Aymen Abdalkader Shaibatalhamd has disclosed a 5.83% beneficial ownership stake in CorMedix Inc., holding 4,600,000 shares.

Deep Track Capital, LP and affiliates have reported a beneficial ownership of 6.29% in CorMedix Inc., totaling 4,955,487 common shares.

A Saudi Arabian individual investor, Shaibatalhamd Aymen Abdalkader, has disclosed a 6.22% beneficial ownership stake in CorMedix Inc.

An amended Schedule 13G filing indicates that SHAIBATALHAMD AYMEN ABDALKADER has reduced their beneficial ownership in CorMedix Inc. to 0%.

Aymen Abdalkader Shaibatalhamd, a Saudi Arabian individual, has disclosed a passive beneficial ownership of 5.4% in CorMedix Inc., holding 3,543,088 shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.5% beneficial ownership stake in Cormedix Inc. as of December 31, 2024.